Abstract
Diabetes mellitus is a growing health concern world-wide. Patients with this disease present with a variety of health conditions, including a number of sight-threatening ocular pathologies. Proliferative diabetic retinopathy (PDR) and diabetic macula edema (DME) are common diseases that cause substantial vision impairment in diabetic patients. There has been a strong focus on studying the epidemiology and treatment of these diseases. The recent discovery of vascular endothelial growth factor (VEGF) and its role in the development of proliferative disease, has led to a movement towards treating PDR and DME with anti-angiogenic medications in conjunction with the standard of care. In this review we present a summary of the origination and progression of PDR and DME. This will be followed by a review of clinical data surrounding new anti-angiogenic treatment modalities.
Keywords: Pegaptanib sodium (Macugen), Proliferative diabetic retinopathy, Diabetic macular edema, Diabetes mellitus
Current Diabetes Reviews
Title: Pegaptanib Sodium for the Treatment of Proliferative Diabetic Retinopathy and Diabetic Macular Edema
Volume: 5 Issue: 1
Author(s): Gian P. Giuliari, David A. Guel and Victor H. Gonzalez
Affiliation:
Keywords: Pegaptanib sodium (Macugen), Proliferative diabetic retinopathy, Diabetic macular edema, Diabetes mellitus
Abstract: Diabetes mellitus is a growing health concern world-wide. Patients with this disease present with a variety of health conditions, including a number of sight-threatening ocular pathologies. Proliferative diabetic retinopathy (PDR) and diabetic macula edema (DME) are common diseases that cause substantial vision impairment in diabetic patients. There has been a strong focus on studying the epidemiology and treatment of these diseases. The recent discovery of vascular endothelial growth factor (VEGF) and its role in the development of proliferative disease, has led to a movement towards treating PDR and DME with anti-angiogenic medications in conjunction with the standard of care. In this review we present a summary of the origination and progression of PDR and DME. This will be followed by a review of clinical data surrounding new anti-angiogenic treatment modalities.
Export Options
About this article
Cite this article as:
Giuliari P. Gian, Guel A. David and Gonzalez H. Victor, Pegaptanib Sodium for the Treatment of Proliferative Diabetic Retinopathy and Diabetic Macular Edema, Current Diabetes Reviews 2009; 5 (1) . https://dx.doi.org/10.2174/157339909787314158
DOI https://dx.doi.org/10.2174/157339909787314158 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELD
Current Cardiology Reviews Metal Catalyzed Oxidation of Alpha-Synuclein – A Role for Oligomerization in Pathology?
Current Alzheimer Research Herbal Natural Products As a Source of Monoamine Oxidase Inhibitors: A Review
Current Topics in Medicinal Chemistry Editorial [Hot Topic:Supramolecular Devices for the High-Throughput Screening of Drugs,Nutrients and Metabolites in Postgenomic Era (Part 3) (Guest Editor: Grzegorz Bazylak)]
Combinatorial Chemistry & High Throughput Screening A Review on Natural Products and Herbs Used in the Management of Diabetes
Current Diabetes Reviews Glycaemic Control: A Balancing Act or A Different Approach?
Current Diabetes Reviews Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction
Current Pharmaceutical Design Oral Factor Xa (FXa) Inhibitors for Treatment of Heparin-induced Thrombocytopenia (HIT)
Current Drug Therapy Adiponectin and its Receptors as Potential Therapeutical Targets
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) <i>Ononis natrix</i> L. Lowers the Blood Glucose Concentration in Wistar Rats with Streptozotocin-induced Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Cardiovascular Benefit of SGLT2 Inhibitors in the Therapeutics of Diabetes Mellitus: A Close Look beyond the Horizon
Current Drug Targets A Critical Appraisal of the Functional Evolution of P2Y12 Antagonists as Antiplatelet Drugs
Current Pharmaceutical Design Hypothalamic Leptin and Ghrelin Signaling as Targets for Improvement in Metabolic Control
Current Pharmaceutical Design The Pleiotropic Effects of Statins in Endocrine Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets The Clinical Spectrum of Nephrogenic Systemic Fibrosis
Current Rheumatology Reviews Role of Pancreatic β-Cell Death and Cell Death-Associated Inflammation in Diabetes
Current Molecular Medicine The Impact of In Vitro Fertilization on the Health of the Mother and the Offspring
Current Women`s Health Reviews Neuroprotection by Resveratrol in Diabetic Neuropathy: Concepts & Mechanisms
Current Medicinal Chemistry The “Aged Garlic Extract” (AGE) and One of its Active Ingredients S-Allyl-LCysteine (SAC) as Potential Preventive and Therapeutic Agents for Alzheimer's Disease (AD)
Current Medicinal Chemistry Diet Bioactive Compounds: Implications for Oxidative Stress and Inflammation in the Vascular System
Endocrine, Metabolic & Immune Disorders - Drug Targets